HIV/AIDS communities and AIDS vaccine research

AIDES / TRT-5Tour Essor14, rue Scandicci93508 Pantin Cedex

Questions from the community ANRS and vaccine trials of therapeutic

vaccines ANRS and recruitment of HIV-

volunteers to participate to vaccine trials (safety issues raised)

Partnership with African NGOs (Réseau Afrique 2000): how far are we from a vaccine?

To stop the spread of AIDS

To be better informed

TRT-5 first met with the ANRS investigators (1999) Aventis (Alvac) in 1999

Attendance to scientific meetings

Internal training sessions (immunologists)

To inform(articles in our newsletters)

To inform(training sessions in Africa)

To inform(symposium on immunology)

To inform

Press releases after the announcement of the results of the ANRS trials

Press release after AIDSVAX results

To link up

Vaccine Working Group

IAVI partnership

Microbicides initiative

To work with ANRS

AC5 Clinical trials: to have two community representatives (voting rights)

AC28 Preventive vaccines: two community representatives (one from the HIV community and one from the volunteers) Modification of design of clinical trials Set up of the long term follow up of

vaccinees

To lobby

Towards the Industry to have access to vaccine preparation (Aventis supplied Orvéac with ALVAC after a TRT-5 meeting)

Authorities to maintain a strong commitment to prolong the ANRS

Within the ANRS, AC28 to finally do a proper work!

To lobby

Within our organization for preventive technologies to be a priority

EU for commitment French government to pursue funding

for a preventive vaccine. Does it have to be only directed to the ANRS?